

# Correlation of Antipsychotic and Prolactin Concentration in Children and Adolescents Acutely Treated with Haloperidol, Clozapine, or Olanzapine

Journal of Child and Adolescent Psychopharmacology  
12, 83-91

DOI: 10.1089/104454602760219126

Citation Report

#	ARTICLE	IF	CITATIONS
2	Reply: Atypical Antipsychotics Mechanisms of Action. Canadian Journal of Psychiatry, 2003, 48, 62-64.	1.9	3
3	A Prospective Study of Hyperprolactinemia in Children and Adolescents Treated with Atypical Antipsychotic Agents. Journal of Child and Adolescent Psychopharmacology, 2004, 14, 350-358.	1.3	60
4	The Effect of Atypical Antipsychotic Agents on Prolactin Levels in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 2004, 14, 359-371.	1.3	44
5	Benefit-Risk Assessment of Atypical Antipsychotics in the Treatment of Schizophrenia and Comorbid Disorders in Children and Adolescents. Drug Safety, 2004, 27, 1135-1156.	3.2	63
6	Metabolic side effects of atypical antipsychotics in children: a literature review. Journal of Psychopharmacology, 2005, 19, 533-550.	4.0	65
7	Elevated Prolactin Levels in Male Youths Treated with Risperidone and Quetiapine. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 893-900.	1.3	35
8	Risperidone-Induced Prolactin Elevation in a Prospective Study of Children, Adolescents, and Adults with Mental Retardation and Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 885-892.	1.3	36
9	Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents. Child and Adolescent Psychiatric Clinics of North America, 2006, 15, 177-206.	1.9	163
10	Female Puberty: Clinical Implications for the Use of Prolactin-Modulating Psychotropics. Child and Adolescent Psychiatric Clinics of North America, 2006, 15, 207-220.	1.9	16
11	Children with Schizophrenia. CNS Drugs, 2006, 20, 841-866.	5.9	68
12	Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 771-791.	0.5	343
13	Risperidone-induced Symptomatic Hyperprolactinaemia in Adolescents. Journal of Clinical Psychopharmacology, 2006, 26, 167-171.	1.4	21
14	Childhood-Onset Schizophrenia. Archives of General Psychiatry, 2006, 63, 721.	12.3	200
15	Serum Levels of Olanzapine and Its N-desmethyl and 2-hydroxymethyl Metabolites in Child and Adolescent Psychiatric Disorders: Effects of Dose, Diagnosis, Age, Sex, Smoking, and Comedication. Therapeutic Drug Monitoring, 2006, 28, 750-759.	2.0	36
16	The Effect of Long-Term Antipsychotic Treatment on Prolactin. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 317-326.	1.3	36
17	Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania. American Journal of Psychiatry, 2007, 164, 1547-1556.	7.2	238
18	An Open-Label Study of Olanzapine in Children and Adolescents with Schizophrenia. Journal of Psychiatric Practice, 2007, 13, 86-96.	0.7	11
19	Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders. Journal of Clinical Psychopharmacology, 2007, 27, 639-661.	1.4	136

#	ARTICLE	IF	CITATIONS
21	Clozapine Treatment of Childhood-Onset Schizophrenia: Evaluation of Effectiveness, Adverse Effects, and Long-Term Outcome. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 1349-1356.	0.5	90
22	Management of psychiatric disorders in children and adolescents with atypical antipsychotics. European Child and Adolescent Psychiatry, 2007, 16, 104-120.	4.7	98
23	Olanzapine for the treatment of bipolar disorder in children and adolescents. Expert Opinion on Pharmacotherapy, 2008, 9, 467-474.	1.8	11
24	Side Effects of Second-Generation Antipsychotics: The Experiences, Views and Monitoring Practices of Australian Child Psychiatrists. Australasian Psychiatry, 2008, 16, 253-262.	0.7	39
25	Antipsychotic Medication in Children and Adolescents: A Descriptive Review of the Effects on Prolactin Level and Associated Side Effects. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 403-414.	1.3	90
26	Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study. British Journal of Psychiatry, 2009, 194, 158-164.	2.8	94
27	Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1496-1501.	4.8	38
28	Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 60-70.	0.5	142
29	Treating bipolar disorder in the early stages of illness. , 0, , 73-83.		0
30	Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatric Disease and Treatment, 2010, 6, 749.	2.2	14
32	Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents. Revista De Psiquiatr�a Y Salud Mental (English Edition), 2010, 3, 152-167.	0.3	1
33	Antipsychotic drug toxicology in children. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 591-608.	3.3	28
34	Management of Schizophrenia in Children and Adolescents. Drugs, 2011, 71, 179-208.	10.9	78
35	Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Research, 2011, 187, 74-79.	3.3	19
36	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. European Neuropsychopharmacology, 2011, 21, 621-645.	0.7	168
37	Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, , .	0.6	16
38	Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. Journal of Psychopharmacology, 2012, 26, 42-51.	4.0	77
39	Efectos secundarios del tratamiento antipsic�tico en ni�os y adolescentes na�ve o quasi-na�ve: dise�o de un protocolo de seguimiento y resultados basales. Revista De Psiquiatr�a Y Salud Mental, 2012, 5, 217-228.	1.8	15

#	ARTICLE	IF	CITATIONS
40	Secondary effects of antipsychotic treatment in naïve or quasi-naïve children and adolescents: Design of a follow-up protocol and baseline results. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2012, 5, 217-228.	0.3	8
41	Les recommandations de prise en charge des complications métaboliques associées aux antipsychotiques de deuxième génération chez les enfants et les adolescents. <i>Paediatrics and Child Health</i> , 2012, 17, 58-118.	0.6	0
42	Pharmacotherapy challenges in patients with first-episode psychosis. <i>Journal of Affective Disorders</i> , 2012, 138, S3-S14.	4.1	52
43	More Than Just Milk: A Review of Prolactin's Impact on the Treatment of Anorexia Nervosa. <i>European Eating Disorders Review</i> , 2012, 20, e85-90.	4.1	2
44	Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994–2010. <i>Microbial Biotechnology</i> , 2013, 7, 122-130.	1.7	39
45	Gynecologic and Reproductive Health Concerns of Adolescents Using Selected Psychotropic Medications. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2013, 26, 7-15.	0.7	9
46	Toxicological assessment of drugs that affect the endocrine system in puberty-related disorders. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1309-1316.	3.3	4
47	Prolactin Serum Concentrations During Aripiprazole Treatment in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 282-289.	1.3	23
48	Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents. <i>Paediatric Drugs</i> , 2013, 15, 217-233.	3.1	76
49	An Open-Label Extension Study of the Safety and Efficacy of Risperidone in Children and Adolescents with Autistic Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 676-686.	1.3	37
50	Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia. <i>European Psychiatry</i> , 2014, 29, 1-10.	0.2	74
51	Management of Adverse Effects of Second-generation Antipsychotics in Youth. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 84-105.	1.9	12
52	Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 548-557.	1.3	15
53	Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 273-281.	2.0	13
54	Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study. <i>CNS Drugs</i> , 2017, 31, 797-808.	5.9	8
55	Hormonal Risk Factors for Osteoporosis: Different Profile Among Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 719-726.	1.3	7
56	Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice. <i>Pharmacological Research</i> , 2020, 152, 104589.	7.1	21
57	Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 873-890.	2.4	13

#	ARTICLE	IF	CITATIONS
58	Metabolic Effects of Clozapine Administration Based on Sex Differences and the Relationships Between Dosage and Prolactin Levels: An Observational Study. <i>Clinical Neuropharmacology</i> , 2021, 44, 205-209.	0.7	2
59	The Short-Term Effects of Risperidone-Induced Hyperprolactinemia on Lipid Metabolism in Drug-Naïve Children and Adolescents. <i>Psychiatry Investigation</i> , 2015, 12, 55.	1.6	5
60	First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2010, 19, 124-37.	0.6	51
61	Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2011, 20, 234-41.	0.6	20
62	Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. <i>Paediatrics and Child Health</i> , 2011, 16, 575-80.	0.6	19
65	A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 374-389.	1.3	8
66	Sex Differences in Serum Prolactin Levels in Children and Adolescents on Antipsychotics: A Systematic Review and Meta-Analysis. <i>Current Neuropharmacology</i> , 2023, 21, 1319-1328.	2.9	0
67	Serious Adverse Drug Reactions to Antipsychotics in Minors with Multiple Disabilities: Preventability and Potential Cost Savings by Therapeutic Drug Monitoring. <i>Pharmacopsychiatry</i> , 0, , .	3.3	2
68	Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2023, 19, 501-509.	3.3	2
69	A Systematic Review of Clozapine Concentrationâ€Dose Ratio from Therapeutic Drug Monitoring Studies in Children and Adolescents Treated with Clozapine for Mental Disorders. <i>Therapeutic Drug Monitoring</i> , 0, , .	2.0	0
70	Association between olanzapine plasma concentrations and treatment response: A systematic review, meta-analysis and individual participant data meta-analysis. <i>Biomedicine and Pharmacotherapy</i> , 2024, 172, 116236.	5.6	0